Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2025-02-05 Board/Management Inform…
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying them of an upcoming Board Meeting scheduled for February 13, 2025. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2024. The letter references compliance with SEBI regulations and mentions the closure of the trading window due to insider trading rules. The document does not contain any financial data or results itself, but is an announcement of a board meeting where financial results will be approved. It is not a full financial report, earnings release, or management discussion. Therefore, this document fits the category of Board/Management Information (MANG), as it announces a board meeting and related corporate governance activity.
2025-02-05 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate submitted under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended December 31, 2024. It is addressed to stock exchanges and signed by the company secretary and the registrar and share transfer agent. The document is short (3829 characters) and primarily serves as a compliance certificate rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is a regulatory compliance certificate confirming share dematerialisation status for a quarter, which fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and does not fit other specific categories.
2025-01-07 English
General Updates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) informing about the change of name of the Registrar and Share Transfer Agent (RTA) of the company. It references Regulation 30 of the SEBI Listing Regulations, which pertains to disclosure of material events. The document includes a certificate of incorporation from the Ministry of Corporate Affairs confirming the name change of the RTA. There are no financial statements, management discussion, or detailed financial data present. The document is essentially an announcement of a corporate event (name change of RTA) rather than a financial report or detailed filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is also not a Board/Management change announcement but a regulatory disclosure about a service provider's name change. Given the nature of the content and the regulatory reference, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-01-03 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) informing about the closure of the trading window pursuant to SEBI regulations related to insider trading. It specifies the trading window closure period around the announcement of quarterly financial results for the quarter ended December 31, 2024. The document does not contain any financial data, results, or detailed report content but is an announcement related to compliance and trading restrictions ahead of financial results disclosure. The document length is short (2593 characters) and it serves as a notification rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS) as a compliance-related announcement rather than an actual financial report or earnings release.
2024-12-25 English
Reply to Clarification- Financial results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India providing clarifications regarding previously submitted financial results for the quarter and half year ended September 2024. It discusses the standalone and consolidated financial results, explains the data of a subsidiary company, and clarifies why standalone and consolidated profit & loss figures are the same. The document references financial results already published on 14th November 2024 and includes no new financial statements or detailed financial data itself. The length is 3960 characters, which is relatively short and the document serves as a clarification note rather than a full financial report. It is not an earnings release or interim report but a regulatory clarification filing. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance-related clarification letter to the stock exchange without substantive financial data or report content.
2024-12-20 English
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited, responding to a query about a significant increase in the price and volume of the company's shares. It clarifies that there is no undisclosed price-sensitive information or impending corporate action affecting the stock price or volume. The letter emphasizes compliance with stock exchange regulations and ongoing disclosure practices. The document is a regulatory communication clarifying market activity rather than a financial report, earnings release, or management discussion. It is short (2840 characters) and serves as a formal regulatory filing to address surveillance concerns. Therefore, it fits best under Regulatory Filings (RNS).
2024-12-06 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.